In vivo mechanisms of resistance to cytarabine in acute myeloid leukaemia

British Journal of Haematology

Volumn 117, Issue 4, 2002, Pages 860-868

  Galmarini, Carlos M ^a   Thomas, Xavier ^b   Calvo, Fabien ^c   Rousselot, Philippe ^d   Rabilloud, Muriel ^e   El Jaffari, Assia ^b   Cros, Emeline ^a   Dumontet, Charles ^a  

^a INSERM   (France)

^b EDOUARD HERRIOT HOSPITAL   (France)

^c ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^d SAINT LOUIS HOSPITAL   (France)

^e CENTRE HOSPITALIER LYON SUD   (France)

Author keywords

5 nucleotidase; Cytarabine; DNA polymerase I; Drug resistance; Leukaemia

Indexed keywords

5' NUCLEOTIDASE; CARRIER PROTEIN; CYTARABINE; CYTIDINE DEAMINASE; DEOXYCYTIDINE KINASE; DNA DIRECTED DNA POLYMERASE ALPHA; DNA TOPOISOMERASE; DNA TOPOISOMERASE (ATP HYDROLYSING); EQUILIBRATIVE NUCLEOSIDE TRANSPORTER 1; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ARTICLE; BLAST CELL; CONTROLLED STUDY; DIAGNOSTIC PROCEDURE; FEMALE; HUMAN; IN VIVO STUDY; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SURVIVAL RATE;

5'-NUCLEOTIDASE; ACUTE DISEASE; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; CYTARABINE; CYTIDINE DEAMINASE; DISEASE-FREE SURVIVAL; DNA POLYMERASE I; DNA TOPOISOMERASES, TYPE I; DNA TOPOISOMERASES, TYPE II; DRUG RESISTANCE, NEOPLASM; EQUILIBRATIVE NUCLEOSIDE TRANSPORTER 1; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LEUKEMIA, MYELOID; LYMPHOCYTES; MALE; MEMBRANE TRANSPORT PROTEINS; MIDDLE AGED; MULTIVARIATE ANALYSIS; P-GLYCOPROTEIN; RETROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 0036280996     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.2002.03538.x     Document Type: Article

References (47)

1. Ara-C affects formation of cancer cell DNA synthesome replication intermediates
2. Characterization of the M(r) 190,000 multidrug resistance protein (MRP) in drug-selected and transfected human tumor cell
3. Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group
4. Isolation and characterization of a deoxycytidine kinase-deficient human promyelocytic leukemic cell line highly resistant to 1-beta-D-arabinofuranosylcytosine
5. Molecular identification of the equilibrative NBMPR-sensitive (es) nucleoside transporter and demonstration of an equilibrative NBMPR- insensitive (ei) transport activity in human erythroleukemia (K562) cells
6. Cytosine arabinoside lesions are position-specific topoisomerase II poisons and stimulate DNA cleavage mediated by the human type II enzymes
7. Deoxycytidine kinase: Properties of the enzyme from human leukemic granulocytes
8. Deoxycytidine kinase and deoxycytidine deaminase values correspond closely to clinical response to cytosine arabinoside remission induction therapy in patients with acute myelogenous leukemia
9. Clinical relevance of P-glycoprotein expression in de novo acute myeloid leukemia
10. Common resistance mechanisms to deoxynucleoside analogues in variants of the human erythroleukaemic line K562
11. Variables predicting response to high dose cytosine arabinoside therapy in patients with refractory acute leukemia
12. Expression of cytoplasmic 5′-nucleotidase in leukemic blasts is an adverse prognostic factor in AML patients treated with cytarabine
13. Expression of high Km 5′-nucleotidase in leukemic blasts is an independent prognostic factor in adults with acute myeloid leukemia
14. Nucleoside analogues: Mechanisms of drug resistance and reversal strategies
15. Incorporation of fludarabine and 1-beta-D-arabinofuranosylcytosine 5′-triphosphates by DNA polymerase alpha: Affinity, interaction, and consequences
16. Sensitivity of acute leukemia cells to cytarabine is a correlate of cellular es nucleoside transporter site content measured by flow cytometry with SAENTA-fluorescein
17. A possible role for topoisomerase II in cell death and N-phosphonoacetyl-L-aspartate-resistance frequency and its enhancement by 1-beta-D-arabinofuranosyl cytosine and 5-fluoro-2′-deoxyuridine
18. Differential inhibition of the human cell DNA replication complex-associated DNA polymerases by the antimetabolite 1-beta-D-arabinofuranosylcytosine triphosphate (ara-CTP)
19. The effects of cytosine arabinoside on RNA-primed DNA synthesis by DNA polymerase alpha-primase
20. Decreased DNA polymerase sensitivity to 1-beta-D-arabinofuranosylcytosine 5′-triphosphate in P388 murine leukemic cells resistant to vincristine
21. Inhibition of DNA polymerase alpha from leukemic and normal human cells by partially thiolated human deoxyribonucleic acids
22. Altered multidrug resistance phenotype caused by anthracycline analogues and cytosine arabinoside in myeloid leukemia
23. Activity of thymidine kinase and of polymerase alpha as well as activity and gene expression of deoxycytidine deaminase in leukemic blasts are correlated with clinical response in the setting of granulocyte-macrophage colony-stimulating factor-based priming before and during TAD-9 induction therapy in acute myeloid leukemia
24. Saturation of intracellular cytosine arabinoside triphosphate accumulation in human leukemic blast cells
25. Topoisomerase II levels and drug sensitivity in adult acute myelogenous leukemia
26. Correlation of cytotoxicity with incorporation of ara-C into DNA
27. Human cytidine deaminase: Purification of enzyme, cloning, and expression of its complementary DNA
28. Acute myeloid leukemia in the elderly: Assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A southwest oncology group study
29. Relationship of 1-beta-D-arabinofuranosylcytosine in plasma to 1-beta-D-arabinofuranosylcytosine 5′-triphosphate levels in leukemic cells during treatment with high-dose 1-beta-D-arabinofuranosylcytosine
30. Overexpression of the major vault transporter protein lung-resistance protein predicts treatment outcome in acute myeloid leukemia
31. Five putative drug resistance parameters (MDR1/P-glycoprotein, MDR-associated protein, glutathione-S-transferase, bcl-2 and topoisomerase IIalpha) in 57 newly diagnosed acute myeloid leukaemias
32. Sensitivity of HEL and K562 cell lines to topotecan correlates with the level of topoisomerase I expression activity
33. Inhibitory effect of 1-beta-D-arabinofuranosylthymine 5′-triphosphate and 1-beta-D-arabinofuranosylcytosine 5′-triphosphate on DNA polymerases from murine cells and oncornavirus
34. P-glycoprotein, lung resistance-related protein and multidrug resistance associated protein in de novo acute non-lymphocytic leukaemias: Biological and clinical implications
35. Incorporation of cytosine arabinoside monophosphate into DNA at internucleotide linkages by human DNA polymerase alpha
36. Human high-Km 5′-nucleotidase effects of overexpression of the cloned cDNA in cultured human cells
37. Metabolism of ara-C by blast cells from patients with ANLL
38. Overexpression of a M(r) 110,000 vesicular protein in non-P-glycoprotein-mediated multidrug resistance
39. Constitutive overexpression of the cytidine deaminase gene confers resistance to cytosine arabinoside in vitro
40. Structural and functional analysis of the cytidine deaminase gene in patients with acute myeloid leukaemia
41. Functional multidrug resistance phenotype associated with combined overexpression of Pgp/MDR1 and MRP together with 1-beta-D-arabinofuranosylcytosine sensitivity may predict clinical response in acute myeloid leukemia
42. Cytidine deaminase and the development of resistance to arabinosyl cytosine
43. Altered sensitivity to 1-beta-D-arabinofuranosylcytosine 5′-triphosphate of DNA polymerase alpha from leukemic blasts of acute lymphoblastic leukemia
44. Mechanisms of resistance of human acute leukaemia cells to cytosine arabinoside
45. Cytosine arabinoside transport and metabolism in acute leukemias and T cell lymphoblastic lymphoma
46. Ara-C differentially affects multiprotein forms of human cell DNA polymerase
47. Inhibition of DNA polymerase-alpha and -beta of calf thymus by 1-beta-D-arabinofuranosylcytosine-5′-triphosphate